+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Mouse liver tissue and Human placenta tissue lysates, Primary antibody: P09793(STT3A Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P09793(STT3A Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The STT3A antibody targets the STT3A protein, a catalytic subunit of the oligosaccharyltransferase (OST) complex located in the endoplasmic reticulum (ER). This complex mediates the N-glycosylation of nascent polypeptides, a critical post-translational modification for protein folding, stability, and trafficking. STT3A, encoded by the STT3A gene, is one of two paralogs (STT3A and STT3B) in mammals, with STT3A primarily involved in co-translational glycosylation during protein synthesis. Dysregulation of STT3A has been linked to congenital disorders of glycosylation (CDG) and cancers, where altered glycosylation impacts cell adhesion, signaling, and metastasis.

STT3A antibodies are widely used in research to study N-glycosylation mechanisms, ER stress responses, and diseases associated with glycosylation defects. These antibodies enable detection of STT3A expression levels via techniques like Western blotting, immunofluorescence, and immunohistochemistry. They also aid in elucidating OST complex assembly and functional interactions. Commercially available STT3A antibodies are typically raised in hosts like rabbits or mice, often validated for specificity using knockout cell lines or siRNA-mediated silencing. Researchers prioritize antibodies with high affinity and minimal cross-reactivity to STT3B to ensure accurate interpretation of isoform-specific roles. Such tools are pivotal in advancing understanding of glycobiology and developing therapeutic strategies targeting glycosylation pathways.